Prospective Grant of Exclusive License: The Development of Therapeutic Agents for the Treatment of Metastatic Breast Cancer and T-cell Lymphoma

Resumo

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Birich Technologies, Inc., of an exclusive evaluation option license to practice the inventions embodied in the following U.S. Patent Applications (and all continuing applications and foreign counterparts): Serial No. 61/045,088 entitled, "COMPOSITIONS AND METHODS FOR DELIVERING INHIBITORY OLIGONUCLEOTIDES" [HHS Ref. E-051- 2008/0-US-01]; Serial No. 61/333,512 entitled, "Peptide Inhibitors of Interferon Gamma and Interleukin 10 Signaling" [HHS Ref. E-167-2010/0- US-01]; and Serial No. 60/987,340 entitled, "Diagnostic and Therapeutic Applications of a p53 Isoform in Regenerative Medicine, Aging and Cancer" [HHS Ref. E-033-2008/0-US-01]. The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide, and the field of use may be limited to: